Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Teceleukin

 
National Institutes of Health

Related topics

Related topics

6 relations
Cytokine Receptor ActivationGene Expression RegulationInhibition of Cell ProliferationInterleukin 2 Receptor
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A Phase I/IIa Study of Antidisialoganglioside Antibody Dinutuximab in Japanese Patients With Neuroblastoma
Japanese patients with neuroblastoma completing induction therapy and high-dose chemotherapy received antidisialoganglioside… Expand
2013
2013
SYNERGY BETWEEN JAK INHIBITOR RUXOLITINIB AND TYROSINE KINASE INHIBITORS TO OVERCOME DRUG RESISTANCE RELATED TO BONE MARROW STROMA MICROENVIRONMENT IN CHRONIC MYELOID LEUKEMIA
Inhibition of the constitutively active kinase BCR-ABL1 with tyrosine kinase inhibitors(TKIs) contributed to a remarkable… Expand
  • figure 8
  • figure 9
  • figure 11
  • figure 12
  • table 2
Review
2012
Review
2012
Interleukin-2
SynopsisRecombinant interleukin-2 (IL-2) products (e.g. aldesleukin, teceleukin) are nonglycosylated, modified forms of the… Expand
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2011
Highly Cited
2011
Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma
Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2006
Highly Cited
2006
Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study
PurposeAlthough various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2000
2000
rIL-2製剤にて薬疹 (紅斑) を呈した悪性血管内皮細胞腫の1例
se of drug eruption after long term rIL-2 therapy is reported.A 67-year-old man had a tumor on his right temporal scalp on June… Expand
1991
1991
A phase II trial of interleukin‐2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma
Fifteen patients with advanced, measurable renal cell carcinoma entered a Phase II clinical trial of interleukin‐2 (IL‐2… Expand
1991
1991
A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma.
Fifteen patients with advanced, measurable renal cell carcinoma entered a Phase II clinical trial of interleukin-2 (IL-2… Expand
1989
1989
Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
Single doses of teceleukin ranging from 0.1 to 30 x 10(6) units were administered to cancer patients as intravenous infusions or… Expand
1989
1989
Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
Single doses of teceleukin ranging from 0.1 to 30 x 10(6) units were administered to cancer patients as intravenous infusions or… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE